PSPHL and breast cancer in African American women: causative gene or population stratification?

Abstract

Background

Phophoserine phosphatase-like (PSPHL) is expressed at significantly higher levels in breast tumors from African American women (AAW) compared to Caucasian women (CW). How overexpression of PSPHL contributes to outcome disparities is unclear, thus, molecular mechanisms driving expression differences between populations were evaluated.

Results

PCR was used to detect deletion of 30-Kb of chromosome 7p11 including the first three exons of PSPHL using genomic DNA from AAW (199 with invasive breast cancer, 360 controls) and CW (invasive breast cancer =589, 364 controls). Gene expression levels were evaluated by qRT-PCR using RNA isolated from tumor tissue and blood. Data were analyzed using chi-square analysis and Mann–Whitney U-tests; P < 0.05 was used to define significance. Gene expression levels correlated with deletion status: patients homozygous for the deletion had no detectable expression of PSPHL, while heterozygous had expression levels 2.1-fold lower than those homozygous for retention of PSPHL. Homozygous deletion of PSPHL was detected in 61% of CW compared to 6% of AAW with invasive breast cancer (P < 0.0001); genotype frequencies did not differ significantly between AAW with and without breast cancer (P = 0.211).

Conclusions

Thus, deletion of 7p11, which prevents expression of PSPHL, is significantly higher in CW compared to AAW, suggesting that this 30-kb deletion and subsequent disruption of PSPHL may be a derived trait in Caucasians. The similar frequency of the deletion allele in AAW with and without invasive breast cancer suggests that this difference represent population stratification, and does not contribute to cancer disparities.

Background

The phosphoserine phosphatase-like (PSPHL [GenBank AJ001612.1]) gene was identified over a decade ago as a gene upregulated in fibroblasts from patients with Fanconi Anemia (FA) [1]. Although the gene shares multiple regions of sequence homology with phosphoserine phosphatase, a 476-bp fragment missing from PSPHL results in an altered coding region. Microarray analysis of the ocular disease pterygia identified PSPHL as one of three genes that could predict disease recurrence; immunohistochemical analysis revealed PSPHL is expressed at the superficial epithelium of the primary but not recurrent pterygia, suggesting that decreased PSPHL is correlated with increasing alterations in the basement membrane [2]. A deletion/insertion (del/ins) polymorphism within the PSPHL gene has also been associated with susceptibility to bipolar disorder [3]. Despite these associations with disease states, the function of PSPHL remains unknown.

Microarray analysis has revealed significantly higher PSPHL expression levels in a variety of tumor types from African Americans compared to Caucasians. For example, studies using gene expression analysis found significantly higher expression of PSPHL in prostate tumors, the surrounding microenvironment, and in primary cell cultures from prostate tumors from African American compared to Caucasian men [4,5]. Higher expression of PSPHL has also been found in breast tumors, the tumor microenvironment and non-malignant breast stroma from African American women (AAW) [6,7]. Expression levels of PSPHL were also found to be significantly higher in endometrial tumors from AAW compared to Caucasian women (CW) [8,9].

This detection of significantly higher levels of PSPHL has been in sex-hormone derived tumors, which have been shown to have less favorable outcomes in African American compared to Caucasian patients [10]. Altered expression of PSPHL in FA suggests that PSPHL may influence rates of cellular proliferation [1], which may promote more aggressive tumor biology and less favorable outcomes. PSPHL is an 841 bp gene spread over four exons on chromosome 7p11.2. The promoter and first three exons of PSPHL are located within a 30 Kb region that is not represented in the human reference sequence, thus individuals harboring this deletion would not express PSPHL. If increased expression of PSPHL drives pro-tumorigenic properties, this may contribute to higher mortality rates in AAW. In contrast, baseline expression of PSPHL is heritable [11], thus higher expression levels of PSPHL may reflect different minor allele frequencies in patients of European compared to African ancestry. To determine whether PSPHL is involved in tumorigenesis or reflects population stratification, the association between retention or loss of the 30 Kb region on chromosome 7p11 and expression levels of PSPHL were investigated in African American and Caucasian populations.

Results

Genomic DNA was available from 199 AAW and 589 CW with invasive breast cancer, and 360 AAW and 364 CW controls. Genotypes were successfully generated for all available specimens. All populations were in Hardy-Weinberg equilibrium. Genotype frequencies were significantly different between AAW and CW with breast cancer (Table 1) but not between AAW with and without breast cancer. In addition, genotype frequencies were not significantly different between CW cases and controls. Deletion (del) allele frequencies were significantly lower in AAW with (0.24) and without (0.19) invasive breast cancer compared to those in CW with invasive breast cancer (0.77) and CW controls (0.81).

Table 1.

Genotype frequencies of the deletion (del)/insertion (ins) polymorphism of 30 Kb on chromosome 7p11 amongst the four patient groups

	Del/Del	Ins/Del	Ins/Ins	P-value
AA case	0.06 (n = 12)	0.35 (n = 70)	0.59 (n = 117)
C case	0.62 (n = 362)	0.34 (n = 202)	0.04 (n = 25)	P < 0.0001a
AA controls	0.04 (n = 13)	0.31 (n = 112)	0.65 (n = 235)	P = 0.211b
C controls	0.64 (n = 232)	0.34 (n = 123)	0.02 (n = 9)	P = 0.336c

AA = African American, C = Caucasian.

^aP-value calculated between African American and Caucasians with invasive breast cancer.

^bP-value calculated between African American cases and controls.

^cP-value calculated between Caucasian cases and controls.

Expression levels for PSPHL were generated by qRT-PCR from 116 tumor specimens (33 AAW and 83 CW) and 49 blood samples, 13 of which overlapped with the tumor samples. Patients with the del/del genotype had no detectable expression in either tissue (n = 49) or blood (n = 23). Expression levels in breast tissue (Figure 1) were 2.1-fold higher in patients homozygous for the insertion allele compared to heterozygotes (P < 0.005), while tissue from patients expressing one or two copies of PSPHL were significantly higher than those patients homozygous for the deletion allele (P < 0.00001). When analyzing blood RNA, expression of PSPHL was significantly higher in carriers of the insertion allele (ins/ins or ins/del) compared to patients homozygous for the deletion allele (<P < 0.005), although PSPHL levels did not differ significantly in blood RNA between heterozygotes (n = 17) and those with the ins/ins genotype (n = 9), which may be attributable to small sample size.

Figure 1.

Graphical representation of expression levels of PHPHL in tumor tissues by genotype. Del/del = homozygous for deletion variant, del/ins = heterozygous, ins/ins = homozygous for insertion variant.

To determine whether expression of PSPHL was associated with aggressive tumor characteristics or survival, the loss (del/del) or retention (ins/del or ins/ins) of the 30 Kb of chromosome 7p was evaluated within each population for a number of clinical factors (Table 2). Although AAW were more likely to be diagnosed at a younger age, with ER-/HER2-, high-grade tumors than were CW, deletion of PSHPL was not associated with any pathological characteristics.

Table 2.

Association between retention or absence of 30 Kb region of chromosome 7p and clinicopathological factors by ethnic group

	AAW			CW
	Del/Del (n = 12)	Del/Ins or Ins/Ins (n = 186)	P-value	Del/Del (n = 343)	Del/Ins or Ins/Ins (n = 220)	P-value
Age			0.475			0.596
<50 years	0.33	0.44		0.27	0.29
≥50 years	0.67	0.56		0.73	0.71
Stage			0.627			0.366
I	0.64	0.55		0.58	0.52
II	0.36	0.32		0.30	0.32
III	0.00	0.08		0.10	0.13
IV	0.00	0.05		0.02	0.03
ER/HER2 status			0.546			0.458
ER+/HER2-	0.50	0.59		0.71	0.68
ER+/HER2+	0.17	0.08		0.09	0.12
ER-/HER2+	0.00	0.06		0.06	0.06
ER-/HER2-	0.33	0.27		0.14	0.14
Grade			0.795			0.340
Low	0.18	0.20		0.35	0.28
Intermediate	0.27	0.36		0.35	0.41
High	0.55	0.44		0.30	0.31
Tumor size			0.792			0.367
T1	0.64	0.64		0.73	0.68
T2	0.36	0.32		0.20	0.26
T3	0.00	0.04		0.07	0.06
Lymph node status			0.576			0.550
Positive	0.18	0.26		0.26	0.29
Negative	0.82	0.74		0.74	0.71
Statusa			0.485			0.091
DOC	0.08	0.02		0.02	0.04
DOD	0.08	0.06		0.07	0.05
AWD	0.00	0.03		0.04	0.01
NED	0.84	0.89		0.87	0.9

^aDOC = dead other causes, DOD = dead of disease, AWD = alive with disease, NED = no evidence of disease.

Discussion

AAW have the highest breast cancer mortality rates in the United States with 32.4/100,000 deaths compared to CW who have a mortality rate of 23.9/100,000 [12]. These differences may be attributable to socioeconomic factors such as access to health-care, however, within clinical trials where treatment was standardized, pre- and post-menopausal African American women demonstrated 40% and 50% increased mortality rates, respectively [10]. Microarray analysis has identified a number of genes differentially expressed in tumors from AAW compared to CW, including SOS1, CRYBB2///CRYBB2P1 and PSPHL. The significantly higher expression of PSPHL in tumors from African Americans coupled with its putative role in processes such as cellular proliferation may be contributing to more aggressive tumor phenotypes and less favorable outcomes in African Americans. Moreover, if altered expression of PSPHL does have a role in tumorigenesis, it becomes a molecular target for the development of new, tailored treatments for the African American population.

Our data demonstrates that the deletion of 30 kb from chromosome 7p11, including the promoter and the first three of four exons of PSPHL, effectively eliminates expression of PSPHL. The allele frequency of retention of this region of chromosome 7p is high in AAW, and only 6% of AAW were homozygous for the deletion and thus did not express PSPHL. In contrast, the retention allele frequency was only 21% in CW and 62% of Caucasian cases expressed no PSPHL. These data thus provide a functional explanation for expression differences across individuals and between populations. Previous data from our laboratory demonstrated that while within populations, expression levels of PSPHL did not differ significantly between tumor and non-malignant stroma, between populations, PSPHL levels were significantly higher in both tumor tissues as well as non-malignant stroma. In addition, higher expression levels of PSPHL in non-malignant tissues from AAW were not associated with higher rates of tumor development [6]. Given the contralateral diagnosis and that none of the other non-malignant patients have progressed to more advanced diagnoses, it is not clear that increased PSPHL is associated with tumorigenesis. In addition, the absence of expression of PSPHL in patients homozygous for the deletion on chromosome 7p was not associated with unfavorable tumor characteristics or survival. In addition to the higher levels of PSPHL in a variety of tumor types, the surrounding tumor stroma and non-malignant breast tissues, significantly higher expression of PSPHL was also detected in blood endothelial cells from healthy African Americans compared to Caucasians [13]. Together with our data demonstrating that the frequency of the insertion allele did not differ significantly between African American cases and controls, these data suggest that PSPHL expression levels are not associated with breast cancer etiology.

Conclusions

Differential expression of PSPHL provides an example of how population stratification may confound identification of genes associated with health care disparities. Given the higher expression levels of PSPHL in breast and prostate tumors from African Americans, a two-gene predictor including PSPHL and CRYBB2 has been proposed to effectively distinguish between tumor epithelia from African American and European Americans [7], however, whether and how these genes play a role in tumor etiology was not determined. Although PSPHL is expressed at higher levels in breast (and other) tumors from African Americans, it is also expressed at significantly higher levels in non-tumor tissues as well as blood. In addition, the frequency of the deletion variant which determines expression levels of PSPHL is significantly higher in Caucasians but does not differ between African American cases and controls. Thus, differential expression of PSPHL caused by retention of a 30 Kb region of 7p11 in individuals of African Ancestry suggests that this difference represent population stratification, and does not contribute to cancer disparities.

Methods

Eligibility and enrollment

For inclusion in the Clinical Breast Care Project (CBCP), all patients must have met the following eligibility criteria: 1) adult over the age of 18 years, 2) mentally competent and willing to provide informed consent, and 3) presenting to participating breast centers with evidence of possible breast disease or for routine mammographic screening. Tissue and blood samples were collected with approval from the Walter Reed National Military Medical Center Human Use Committee and Institutional Review Board. All subjects enrolled in the CBCP voluntarily agreed to participate and gave written informed consent. Clinical information was collected for all CBCP samples using questionnaires designed by and administered under the auspices of the CBCP.

Deletion/insertion polymorphism detection and gene expression analysis

Genomic DNA (AAW invasive = 199, AAW control = 360, CW invasive = 589, CW controls = 364) was isolated from blood clots using the Gentra Clotspin and Puregene DNA purification kits (Qiagen., Valencia, CA). The del/ins polymorphism was assessed using the primer sets described in [3], and the resulting PCR products run on 2% agarose gels (Figure 2). Hardy-Weinberg equilibrium was determined for each population using the OEGE- Online Encyclopedia for Genetic Epidemiology studies Hardy-Weinberg equilibrium calculator (http://www.oege.org/software/hwe-mr-calc.shtml). RNA was isolated from tumor specimens (n = 116) after laser microdissection as previously described [6]. RNA was isolated from blood samples (n = 49) collected in PAXgene Blood RNA tubes (Becton Dickinson, Franklin Lakes, NJ) and isolated using the PAXgene Blood RNA Kit IVD (Qiagen, Valencia, CA) according to manufacturer’s recommendations.

Figure 2.

PCR detection of deletion or insertion of PSPHL gene. The forward primer that detects the deletion allele spans the deletion breakpoint on chromosome 7p and the primer pair amplifies a 793 bp fragment. The primers that detect the insertion product amplify a 208 bp fragment from exon 1 of PSPHL. Genotypes shown here are A = del/del, B = del/del, C = ins/del, D = ins/ins, and E = ins/del. Primers used are (all in 5′-3′ direction - insertion forward: AGGCTCCCTGGCTGGC, insertion reverse: CAGGCTCAGGTGAGGCG, deletion forward: AAGCCAGTGCGTCTACAGGTG, deletion reverse: GTGCCAGAAGAACCACACAGTC.

For qRT-PCR, RNA was reverse transcribed using the High-Capacity cDNA Reverse Transcription kit (Life Technologies, Grand Island, NY). qRT-PCR was performed using TaqMan gene expression assay Hs00863464_m1 (Life Technologies, Grand Island, NY). Amplification was performed in duplicate using TaqMan Universal PCR Master Mix (Life Technologies, Grand Island, NY). GAPDH was used as the endogenous control for normalization of all assays. Relative quantification of gene expression levels was determined using the Comparative C_t method [14].

Statistical analysis

Allele and genotype frequencies were compared between AAW with and without invasive breast cancer and between AAW and CW with invasive breast cancer by chi-square analysis using rxc Contingency Tables. For qRT-PCR data, the medians of the 2^-ΔΔCt values were compared using a Mann–Whitney U test to determine if the relative fold change was significantly different (two-tailed) between genotypes. Significance was determined using P < 0.05.

Competing interest

The authors declare that they have no competing interests.

Authors’ contributions

SR developed protocols for testing the insertion/deletion, generated gene expression data and participated in the writing of the manuscript, CP genotyped the ins/del variant, CDS oversaw collection of all patient samples and reviewed the manuscript; REE designed the project, performed data analysis and wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgements

This research was supported by a grant from the United States Department of Defense (Military Molecular Medicine Initiative MDA W81XWH-05-2-0075, Protocol 01–20006). The opinion and assertions contained herein are the private views of the authors and are not to be construed as official or as representing the views of the Department of the Army or the Department of Defense.